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Fungal infections arise frequently in immunocompromised
patients, and sterol synthesis is a primary pathway targeted by
antifungal drugs. In particular, the P450 protein Erg11/Cyp51
catalyzes a critical step in ergosterol synthesis, and the azole
class of antifungal drugs inhibits Erg11. Dap1 is a heme-binding
protein related to cytochrome b5 that activates Erg11, so that
cells lacking Dap1 accumulate the Erg11 substrate and are
hypersensitive to Erg11 inhibitors. Heme binding by Dap1 is
crucial for its function, and point mutants in its heme-binding
domain render Dap1 inactive for sterol biosynthesis and DNA
damage resistance. Like Dap1, the human homologue,
PGRMC1/Hpr6, also regulates sterol synthesis and DNA dam-
age resistance. In the present study, we demonstrate that the
Dap1heme-1domain is required for growthunder conditions of
low iron availability. Loss of Dap1 is suppressed by elevated lev-
els of Erg11 but not by increased heme biosynthesis. Dap1 local-
izes to punctate cytoplasmic structures that co-fractionate with
endosomes, andDap1 contributes to the integrity of the vacuole.
The results suggest that Saccharomyces cerevisiae Dap1 stimu-
lates aP450-catalyzed step in sterol synthesis via a distinct local-
ization from its homologues in Schizosaccharomyces pombe and
mammals and that this function regulates iron metabolism.
Fungal infections are important clinically because they con-
tribute to the mortality of patients with human immunodefi-
ciency virus/AIDS, cancer, and other diseases associated with
immunosuppression. Mammalian hosts combat fungal infec-
tions via the immune system and by sequestering free iron in
the bloodstream. Fungal infections can be suppressed with the
azole group of antifungal drugs, a commercially important
group of drugs that includes fluconazole, itraconazole, and
miconazole. These drugs inhibit Erg11/Cyp51/lanosterol dem-
ethylase (1, 2), which catalyzes a critical step in the synthesis of
ergosterol, a key component of the fungal cellmembrane. Erg11
is one of a large class of monooxygenases that are called P450
proteins due to the spectral absorbance of a cysteine-linked
heme molecule in their active site (3).
In Saccharomyces cerevisiae, Erg11 is activated by Dap1
(damage resistance protein 1) (4), which is related to cyto-
chrome b5 (5), a heme-binding protein that activates P450 reac-
tions (3, 6). Cells lackingDap1 partially arrest sterol synthesis at
the stage catalyzed by Erg11 (4), and dap1 cells are hypersen-
sitive to the Erg11 inhibitors itraconazole and fluconazole (4).
According to microarray databases, DAP1 expression is
induced by azole antifungal drugs (7), but this has not been
independently confirmed. Azole sensitivity in dap1 cells is
suppressed by overexpressing Erg11 (8), and dap1 cells have
4-fold lower levels of Erg11 than wild-type cells (8), although
this regulation occurs primarily at the post-transcriptional
level. Notably, the effect of Dap1 on sterol synthesis is con-
servedwith its humanhomologue (9), called PGRMC1 (for pro-
gesterone receptor membrane component 1) or Hpr6 (for
heme-1 domain protein/human progesterone receptor) (10).
Dap1 binds to heme (8, 11), as does its homologues in Schiz-
isaccharomyces pombe, mice, and humans (9, 12, 13). The
heme-binding activity of Dap1 is critical for its function, and
heme-binding defective mutants are inactive in sterol synthesis
or damage resistance (8). Furthermore, the damage sensitivity
and sterol synthesis phenotypes of dap1 mutants can be sup-
pressed by adding exogenous heme (8), suggesting a role for
Dap1 in maintaining heme metabolism. One appealing model
for Dap1 family proteins is that they utilize their heme-binding
activity to directly activate P450 proteins. However, unlike
cytochromes and related proteins, Dap1 homologues lack the
histidine residues that coordinate heme binding in cytochrome
b5 (5), suggesting that Dap1 may participate in intracellular
heme trafficking. In addition to regulating ergosterol synthesis,
Dap1 is required for resistance to the alkylating agent methyl
methanesulfonate, and dap1 cells have decreased mitochon-
drial function (4).
Heme (iron protoporphyrin IX) is synthesized in an eight-
step pathway that is subject to regulation at various steps (14).
Two key steps in heme synthesis are catalyzed byHem1/5-ami-
nolevulinate synthase, a mitochondrial protein, and Hem2/-
aminolevulinate dehydratase/porphobilinogen synthase, which
localizes to the cytoplasm and nucleus. Heme and ergosterol
share the same upstream precursors (15), and the synthesis of
heme and ergosterol are closely synchronized. The Hap1 tran-
scription factor (16) is directly regulated by heme through a
series of heme-regulated sequence motifs that control multi-
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protein complex formation andDNAbinding (17).Heme is also
required for the transcription of iron transport and sterol syn-
thetic genes (18). Iron levels, in turn, regulate the transcription,
post-transcriptional stability, and post-translational levels of
numerous genes and gene products (19–21). One of the iron-
regulated transcripts is DAP1, which is post-transcriptionally
regulated by proteins that respond to low iron conditions (19).
Because of the close relationship between iron metabolism
and the synthesis of heme and ergosterol, we have examined the
role of Dap1 in these processes. We have found that Dap1 reg-
ulates growth under low iron conditions through a mechanism
that requires its heme-1 domain, and Dap1-mediated growth
on low iron is mediated by Erg11. We have also shown that
Dap1 localizes to endosomes and regulates the structure of the
vacuole, which is characteristic of other sterol biosynthetic pro-
teins. The results represent a novel function for theDap1 family
proteins, which include homologues in mammals that are
important for sterol synthesis and in cancer.
EXPERIMENTAL PROCEDURES
Yeast Strains and Growth Conditions—All strains were iso-
genic with W303 (leu2-3,112 his3-11,15 ura3-1 ade2-1 trp1-1
can1-100 rad5-535) (22). The rad5-535 allelewas replacedwith
the wild-type RAD5 gene by crossing and tested by PCR as
described (23). Cells were maintained yeast-peptone-dextrose
(YPD)2 or synthetic dextrose plates. Methyl methanesulfonate
(Sigma) and bathophenanthroline disulfonic acid (Fisher) were
added to plates at the indicated doses. For expression studies,
log phase cultureswere treatedwith itraconazole,methylmeth-
anesulfonate, or hydroxyurea (all from Sigma) at the indicated
doses.
The strains RCY409-2a (DAP1) and RCY409-4b (dap1::
LEU2) and the RCY409-2a and RCY409-4b derivatives harbor-
ing the control (pRS313, YEplac181, or YEplac195), DAP1
(pRC41), DAP1-D91G (pRC39), or ERG11 (pRH4) plasmids
have been described previously (8). The pSCCC1 plasmid has
also been described previously (24). The dap1::HIS3 strain
RCY456 was constructed by one-step transplacement of the
entire DAP1 gene with a PCR product containing HIS3 and
DAP1-flanking homology. Oligonucleotide sequences are
available as supplemental Fig. 1. For Dap1 expression studies,
the DAP1 open reading frame was fused in frame with three
copies of the HA epitope tag sequence by one-step integration
of the epitope tag fused to the KanMX reporter gene. The HA
tag sequence was amplified by PCR with the primers DAP1-
TAGF and DAP1-TAGR, using the plasmid pFA6a-3HA-
KanMX6 (25) as a template. W303a cells were transformed
with the resulting PCR product, and Geneticin-resistant iso-
lates were tested for insertion of the epitope tag by PCR.
The resulting strain, RCY172, was crossed to the strain
RCY308-7b ( mec1-21 CAN1 RAD5) (26), and the resulting
diploid strain, RCY408, was sporulated and dissected, yielding
the wild-type progeny RCY408-1d ( DAP1 CAN1 RAD5) and
RCY408-4b (a DAP1 CAN1 RAD5) and the DAP1-HA deriva-
tives RCY408-1b (a DAP1::3HA-KanMX CAN1 RAD5) and
RCY408-5b ( DAP1::3HA-KanMX CAN1 RAD5). The two
former strains were mated to produce the wild-type diploid
RCY410, and the two latter strains produced the DAP1-HA
diploidRCY411,whichwere used for immunofluorescence. For
Erg11-Myc staining, RCY411 was transformed with pRH7 (8),
which encodes Erg11 fused to a singleMyc epitope tag. All genetic
manipulations were performed using standard conditions.
Plasmids—The plasmid pJM63, encoding HEM1, was pre-
pared by amplifying the entire HEM1 gene using the primers
HEM1-300F-Bam and HEM11722R-Eco and subcloning
the product into the plasmid YEplac195. Similarly, HEM2
was amplified with the primers HEM2-300F-Hind and
HEM21028R-Eco and subcloned into YEplac195, forming the
plasmid pJM64. For NSG1 overexpression, the entire NSG1 gene
was amplified using the primers NSG1-300F and NSG1873R-
Myc and was initially subcloned into the PCR cloning plasmid
pCR2.1, forming the plasmid pJM76. TheNSG1 fragmentwas the
liberated as a XhoI-BamHI fragment and subcloned into the SalI
and BamHI sites of YEplac195, forming the plasmid pJM77.
FET3 Promoter Assays—The FET3-lacZ plasmid, consisting
of the FET3 promoter fused to lacZ in the plasmid YEp354, was
the kind gift of Dr. Jerry Kaplan and has been described previ-
ously (27). For lacZmeasurement, cells were grown in synthetic
medium, with or without 100Mbathophenanthroline disulfo-
nic acid (BPS) for 3 h. The A600 was measured, and the cells
were centrifuged and lysed with 250 l of the Y-PER solution
(Pierce), and the lysatewas incubatedwith 700l of Z buffer (60
mMNa2HPO4-7H2O, 40mMNaH2PO4-H2O, 10mMKCl, 1mM
MgSO4, and 50 mM -mercaptoethanol) containing 1 mg/ml
o-nitrophenyl -D-galactopyranoside. The reaction was
stopped with 500 l of 1 M Na2CO3, clarified by centrifugation,
and measured at 420 nm, using the same concentrations of
Y-PER, Z buffer, and Na2CO3 as a blank. Miller units ((A420 
1000)/(A600/min/ml)) were calculated for each point. FET3
transcription was assayed independently by reverse tran-
scription-PCR as described previously (8) with the FET3
primers FET3100F (ACAGGAACGTTGATGGGCTA)
and FET3380R (GAATGGTACCAGTAGGTGCC). Primers
for the SCS2 transcript (8) served as a control for loading and
were included in the same reaction as for FET3, and the prod-
ucts were separated in 2% agarose. Assays for ferric reductase
activity were performed as described previously (28).
Protein Analysis—Log phase yeast cultures were lysed in
Y-PER lysis solution (Pierce) containing 1 mM phenylmethyl-
sulfonyl fluoride and 10 g/ml aprotinin and analyzed essen-
tially as described (8). The antibody to HA (HA11) was from
BabCo, and the antibody to -tubulin was developed by J.
Frankel and was obtained from the Developmental Studies
Bank at the University of Iowa under the auspices of the
NICHD, National Institutes of Health.
For cell fractionation, cell fractions were separated by
sucrose gradient essentially as described (29). Briefly, 500 ml of
log phase cells were arrestedwith the addition of 10mM sodium
azide, chilled on ice water, and then centrifuged at 4000  g for
10 min. Cells were resuspended in spheroplasting buffer (1 M
sorbitol, 100 mM Tris, pH 7.8, 10 mM EDTA, and 0.3 mg/ml
zymolase) and incubated at 30 °C for 40min. Spheroplasts were
2 The abbreviations used are: YPD, yeast-peptone-dextrose; HA, hemaggluti-
nin; MOPS, 4-morpholinepropanesulfonic acid; BPS, bathophenanthroline
disulfonic acid; MMS, methyl methanesulfonate.
Dap1 Regulates Iron Metabolism
36544 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 50 • DECEMBER 14, 2007
then centrifuged at 700  g for 10min and resuspended in 5ml
of lysis buffer (0.8 M sorbitol, 10 mM MOPS, pH 7.2, and 1 mM
EGTA) containing 1 mM phenylmethylsulfonyl fluoride. The
cells were then lysed with three 10-s pulses from a Polytron
PT1200 homogenizer, and the homogenate was centrifuged at
2500  g for 10 min to remove unlysed cells. One ml of the
lysate was separated on a discontinuous 12–60% sucrose gra-
dient by centrifugation at 100,000 g for 16 h. at 4 °C. Fractions
were collected and analyzed by Western blot using antibodies
to the peroxisome marker Ypt7 (a kind gift from Dr. William
Wickner), the mitochondrial marker Por1 (Molecular Probes),
the lipid particle marker Erg6 (a kind gift from Dr. Gunther
Daum), the endosomal marker Pep12 (Molecular Probes), the
plasma membrane ATPase Pma1 (a kind gift from Dr. Ramon
Serrano), and Erg11 (8).
Fluorescence—Staining was performed largely as described
(29). Log phase diploid cells were fixed with 3.7% formaldehyde
at 37 °C for 30 min, centrifuged, resuspended in 1 M sorbitol
containing 3.7% formaldehyde, and rotated at 4 °C overnight.
Cells were spheroplasted in 1 M sorbitol containing 10 g/ml
zymolase and 70 mM -mercaptoethanol at 30 °C for 1 h,
washed once in PBS, and applied to a poly-L-lysine-coated slide.
Cells were then permeabilized with ice-cold methanol, blocked
with phosphate-buffered saline containing 1 mg/ml bovine
serum albumin, and stained with the HA11 monoclonal anti-
body (BabCo) for Dap1-HA and an anti-Myc tag antibody
(Genscript) for Erg11-Myc, followed by fluorescein isothiocya-
nate-conjugated secondary antibodies. For FM4–64 staining,
cells were incubated with 20 M FM4–64 (Molecular Probes)
in YPDmedium for 10min, washed, and incubated for an addi-
tional 10 min in YPD before microscopic analysis. In all cases,
cells were examined using a Zeiss microscope, and images were
captured using Axioskop software.
Sterol Analysis—200ml of early log phase cells were grown in
YPD medium and treated with 100 M BPS for 3 h. Cells were
pelleted and washed once with distilled water and extracted
with potassium hydroxide-ethanol. Sterols were subsequently
extracted with hexane, as described previously (4, 8), and ana-
lyzed by gas chromatography at the University of Kentucky
Mass Spectrometry Facility.
RESULTS
Strains Lacking Dap1 Are Sensitive to Iron Depletion—Wild-
type and dap1 strains were maintained on iron-depleted
medium by culturing in 100 M BPS.Wild-type cells grew nor-
mally, whereas the dap1 strains did not (Fig. 1A, columns 3
and 4). A small zone of residual growth in the dap1 strain was
dark red and consisted of nonbudded cells with a disrupted
morphology. The BPS sensitivity of dap1 cells was comple-
mented by the wild-type DAP1 gene (Fig. 1B, row 7) but not by
theDAP1-D91Gmutant (Fig. 1B, row 8), which does not bind to
heme (8). The results suggest that the heme binding function of
Dap1 is required for growth under iron-depleted conditions.
The expression of the multicopper oxidase Fet3 is induced
under iron-depleted conditions (30). A construct containing
the FET3 promoter fused to the bacterial lacZ gene was used to
measure FET3 expression. FET3 increased 22-fold in wild-type
cells and 31-fold in dap1 cells following iron depletion (Fig.
1C), a difference that was statistically significant (p 5 106,
two-tailed t test). The difference in FET3 transcription in BPS-
treated wild-type and dap1 cells was confirmed using using
reverse transcription-PCR, where we reproducibly detected a
25% increase in FET3 levels (Fig. 1D). Despite increased FET3
transcription, we did not detect any change in the uptake of
radiolabeled iron or iron reductase activity (50.5  2.8 nmol of
Fe2/min/A600 for wild type versus 52.6  5.0 for dap1). The
results suggest a disparity between iron-regulated transcription
and iron uptake in dap1 cells.
Because Dap1 regulates sterol synthesis, we tested the effect
of the Dap1 mutation on sterol biosynthesis under low iron
conditions. As expected, dap1 cells had elevated lanosterol
and episterol relative to wild-type cells (Fig. 2, compare A and
C). Treatment of wild-type cells with BPS caused a modest
accumulation of episterol (Fig. 2B), whereas dap1 cells accu-
mulated increased levels of squalene (Fig. 2D), suggesting an
iron-related defect in Erg1 function in dap1 cells. The sterol
synthetic pathway is diagrammed in Fig. 2E. Although the Erg1
substrate was elevated under iron-depleted conditions, multi-
copy expression of Erg1 did not suppress BPS sensitivity in
dap1 cells (Fig. 2F, bottom, compare bottom rows), indicating
that altered Erg1 function is not directly related to iron meta-
bolic defects in dap1 cells.
Erg11 Suppresses the Requirement for Dap1 in Iron
Metabolism—Because Dap1 requires heme binding for sterol
synthesis, damage resistance, and viability in low iron,we devel-
FIGURE 1. Dap1 is required for growth under iron-depleted conditions.
A, wild-type (RCY409-2a) or dap1 (RCY409-4b) cells were serially diluted 1:10
and tested for viability on normal growth medium (rows 1 and 2) or the same
medium containing 100 M BPS, an iron-chelating agent. The dap1 strain
grew poorly, and the residual colonies exhibited a dark red color. B, wild-type
cells harboring a control vector (rows 1 and 5) or dap1 cells harboring the
control plasmid pRS313 (rows 2 and 6), the DAP1 expression plasmid pRC41
(rows 3 and 7), or the DAP1-D91G expression plasmid pRC39 (rows 4 and 8)
were tested for growth on control medium (rows 1– 4) or medium containing
BPS (rows 5– 8). DAP1-D91G encodes a point mutant of Dap1 that is incapable
of binding to heme. The wild-type DAP1 gene complemented the dap1
mutation, whereas the DAP1-D91G mutant did not, demonstrating a require-
ment for heme binding for growth on BPS. C, Dap1 suppresses the expression
of iron-regulated genes. Wild-type or dap1 cells harboring a FET3-lacZ con-
struct were untreated (light gray columns) or were treated with 100 M BPS
(dark gray columns), and -galactosidase activity was determined in triplicate.
Error bars, the S.D. between individual measurements. D, FET3 transcripts ana-
lyzed by reverse transcription-PCR in which wild-type cells (lanes 2 and 3) or
dap1 cells (lanes 4 and 5) were untreated (lanes 2 and 4) or treated with 100
M BPS (lanes 3 and 5) for 3 h. Primers directed to the SCS2 transcript, which is
not regulated by iron, were included as an internal control for cDNA loading
(lower band, labeled CON for “control”), and lane 1 is a negative control in
which the RNA template from the sample in lane 2 was amplified without added
reverse transcriptase. The numbers below each lane indicate the FET3/control
ratio relative to the untreated wild-type cells in lane 2. For each assay, the results
shown represent experiments that were performed at least in triplicate.
Dap1 Regulates Iron Metabolism
DECEMBER 14, 2007 • VOLUME 282 • NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 36545
oped a genetic system for increasing heme levels. The HEM1/
-aminolevulinate synthase and HEM2/-aminolevulinate
dehydratase genes were expressed at high copy numbers using
the multiple copy plasmid YEplac195, and this suppressed the
elevated susceptibility of dap1 cells to the alkylating agent
methyl methanesulfonate (MMS) (Fig. 3A). The effect was
more pronounced for HEM2 than HEM1 (Fig. 3A, rows 11 and
12). However, HEM1 and HEM2 high copy expression did not
suppress itraconazole sensitivity, suggesting that the expres-
sion of these genes is not limiting for sterol synthesis (Fig. 3A,
rows 17 and 18). Nsg1 is the yeast homologue of the human
Insig-1 protein, which binds to the human Dap1 homologue
(31). However, a high dosage of NSG1 did not suppress MMS,
itraconazole, or BPS susceptibility in dap1 cells (data not
shown).
Although the heme-binding domain of Dap1 was required
for MMS resistance, high dose expression of HEM2 did not
suppress BPS sensitivity in dap1 cells (Fig. 3B, row 11). In
contrast, high dosage of ERG11 completely suppressed BPS
sensitivity (Fig. 3B, row 12). This effect was not generalized to
other sterol biosynthetic genes, because high dosage of ERG1
and ERG5 had no effect on BPS sensitivity in dap1 strains
(data not shown). Dap1 binds to heme and is related to cyto-
chrome b5, encoded by CYB5 in S. cerevisiae, but high copy
expression of CYB5 did not suppress loss of Dap1 (data not
shown).
Because ERG11 suppressed loss of DAP1, we tested the
extent to which Erg11 inhibitors affected growth on iron-de-
pleted medium. We detected partial growth of wild-type cells
on 2 M itraconazole and 100 M BPS (Fig. 3C, rows 2 and 3,
respectively) but essentially no growth when the two com-
pounds were combined (Fig. 3C, row 4). Taken together, the
results suggest that sterol synthesis mediated by Erg11 and
Dap1 is required for survival in iron-depletedmedium, and this
Dap1 function is not a general property of cytochrome-like
proteins.
Characterization of Dap1—We fused three copies of the HA
epitope tag sequence through one-step integration to the 3 end
of the DAP1 gene. As a result, DAP1 was transcribed from its
own promoter and synthesized from a single copy of its gene.
The tagged Dap1 protein was readily detected as a 25-kDa pro-
tein by Western blot (Fig. 4A, top, lanes 2 and 3). In contrast,
strains lacking the in frame epitope tag did not have a detectable
27-kDa protein (Fig. 4A, top, lane 1). Thus, the migration of
Dap1 was similar to that of related rat and human proteins. In
all cases, blots were probed with an antibody to tubulin as a
control for protein loading (Fig. 4A, bottom).
Dap1 expression was reported previously to change upon
treatment with the antifungal triazole drug itraconazole (7),
and dap1 mutants are sensitive to itraconazole (4, 8). The
expression of Dap1 increased 14-fold in cells treated with 0.1–1
M itraconazole in a dose-dependent manner (Fig. 4B). In con-
trast, Dap1 expression did not change significantly following
treatment withMMS, heat shock, or hydroxyurea (supplemen-
tal Fig. 2A). In addition, we did not detect any changes in Dap1
expression following treatment with BPS (supplemental Fig.
2B) or in strains with elongated or shortened telomeres (tel1
or rif1 rif2, respectively; supplemental Fig. 2C) or in strains
with acute damage sensitivity (mec1-21, rad9, or dun1).
Dap1 Localizes to Punctate Cytoplasmic Sites and Co-frac-
tionates with Endosomal Markers—A diploid strain expressing
the tagged Dap1 protein (Fig. 4A, lane 4), which was not
expressed in the control untagged diploid strain (Fig. 4A, top,
lane 5) was stained by immunofluorescence with the HA anti-
body. Dap1 localized to bright, clearly defined spots within the
cytoplasm (Fig. 4C; bright field in Fig. 4D). The spots varied in
size and number between the cells and were detectable in both
mother and daughter cells. There was no evidence for Dap1
staining within the mother-bud neck, within the nucleus, or at
the cell periphery. In contrast, the control diploid strain did not
stain with the HA antibody after the same procedure (Fig. 4E;
bright field shown in Fig. 4F). Similar spots of Dap1 staining
were detected in haploid strains but weremore difficult to visu-
alize due to the smaller cell size.
Punctate cytoplasmic staining is characteristic of several
types of subcellular structures. Thus, the subcellular fractions
of a Dap1-tagged strain were separated on a sucrose gradient
FIGURE 2. Effect of iron deprivation on sterol synthesis. Wild-type
(RCY409-2a) (A and B) and dap1 (RCY409-4b) (C and D) were untreated
(A and C) or were treated with 100 M BPS for 3 h (B and D). Sterols were
extracted and analyzed by gas chromatography. In wild-type cells, iron deple-
tion led to a modest increase in episterol levels, whereas cells lacking Dap1
had elevated levels of episterol and lanosterol, as published previously (4),
and iron depletion led to a further accumulation of squalene. E, the sterol
biosynthetic pathway is diagrammed, showing the positions of the sterol
intermediates that are highlighted in A–D, as well as the relevant activators
and inhibitors. F, wild-type and dap1 cells containing a control multicopy
plasmid or a multicopy plasmid harboring ERG1 were tested for growth on
control medium (top) or medium containing BPS (bottom). High copy expres-
sion of ERG1 did not suppress iron sensitivity in dap1 cells.
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and probed for Dap1 or various markers. Dap1 co-fractionated
with Ypt7 (Fig. 5, A and B), a GTP-binding protein that regu-
lates vacuolar transport (32), indicating that Dap1 co-localizes
with endosomal proteins. Dap1 also partially co-fractionated
with Pep12, aQA-type SNARE/syntaxin (33) that is amarker for
late endosomes (Fig. 5C). In contrast, Dap1 did not co-fraction-
ate with Erg6/sterol C-24 methyltransferase, a marker for lipid
particles (Fig. 5D) (34, 35) or with Por1/porin, a voltage-gated
anion channel andmarker formitochondria (Fig. 5E). The find-
ing that Dap1 did not co-fractionate with Erg6 is consistent
with an earlier mass spectrometric analysis of abundant pro-
teins in purified lipid particles, which did not identify Dap1
(34, 36).
Mass proteomic screens for interacting proteins have identi-
fied the plasma membrane ATPase Pma1 as a putative Dap1-
binding protein (37). However, our gradient detected Pma1 in a
distinct portion of the gradient fromDap1 (Fig. 5F). Dap1 inter-
acts genetically with Erg11 and stabilizes Erg11 expression (8).
Erg11 localization was diffuse throughout the sucrose gradient
(Fig. 5G), and Erg11 staining by immunofluorescencewas gran-
ular and excluded from the vacuole (Fig. 5H). Previous studies
withGFP-tagged Erg11 derivatives localized Erg11 to the endo-
plasmic reticulum (38), cytoplasm (35), or granular sites (39).
Ypt7 is related to themammalian Rab7 protein and regulates
the movement of proteins from the prevacuolar compartment
to the vacuole (32). We tested the role of Dap1 in vacuolar
structure by incubating wild-type and dap1 cells with the flu-
orescent dye FM4-64, which is internalized and stains the yeast
vacuole (40). In wild-type cells, vacuoles stained as circular
structures (Fig. 6C; the bright field image is shown in Fig. 6A),
whereas in dap1 cells, a significant fraction of vacuoles con-
sisted of multiple smaller structures that resembled unfused
vesicles (Fig. 6D), and others con-
tained irregular edges or a central
septum. The color version of this
figure is supplemental Fig. 3. The
percentage of cells with aberrant
vacuoles was elevated in dap1 cells
(23  5%) compared with wild type
(7  3%) to a significant extent (p 
0.006, two-tailed t test).
Defective vacuolar structure
could inhibit vacuolar iron storage.
In wild-type cells harboring a CCC1
(cross-complements Ca2 pheno-
type of csg1 (41); csg is an abbrevia-
tion for calcium-sensitive growth)
high copy plasmid, FET3-lacZ
reporter activity was highly induced
(Fig. 6E), most likely due to iron
being sequestered in the vacuole. In
dap1 cells harboring the same
CCC1 plasmid, FET3-lacZ activity
was diminished by 40% (Fig. 6E), a
significant difference (p  0.011,
two-tailed t test). Decreased FET3
transcription in CCC1-expressing
dap1 cells was almost identical
when FET3 transcripts were assayed using an independent PCR
technique (Fig. 6F, compare lanes 3 and 5). We detected a 38%
decrease in FET3 transcripts in dap1 cells expressing CCC1
compared with comparable wild-type cells when calculated
from theFET3/control transcript ratios (shown at the bottom of
Fig. 6F). In triplicate analyses, the difference in FET3 levels
between CCC1-overexpressing wild-type and dap1 cells was
statistically significant (p  0.02, two-tailed t test). This finding
is consistent with a diminished ability of CCC1 to direct iron
storage in dap1 cells. We note that the CCC1 high copy plas-
mid did not affect growth of dap1 cells under low iron condi-
tions, consistent with an additional defect in iron uptake.
DISCUSSION
Iron utilization in fungi is important clinically because the
availability of free iron limits the growth of pathogenic yeast. In
dap1 cells depleted of iron, ERG11 activity is inhibited, caus-
ing toxic levels of lanosterol to accumulate. This effect is
reversed by ERG11 overexpression but not by elevated heme. It
is unclear why iron depletion is toxic to cells containing ele-
vated levels of lanosterol. One potential explanation is that the
pathway that detoxifies lanosterol requires iron. Thus, deletion
of DAP1 increases lanosterol levels, and iron depletion
increases its toxicity (diagrammed in Fig. 7). This model is sup-
ported by our finding that BPS increases susceptibility to azole
drugs and by similar findings in C. albicans (42).
In cells lacking Dap1, iron deprivation triggers increased
induction of FET3 expression, but increased FET3 levels do not
lead to increased iron uptake or iron reductase activity, suggest-
ing that the sterol imbalance in dap1 cells interferes with iron
uptake. The model that sterol synthesis promotes iron metab-
olism is consistent with the findings of Li and Kaplan, in which
FIGURE 3. MMS resistance is maintained by a Dap1-mediated pathway that is distinct from resistance to
azole antifungal drugs and BPS. A, wild-type and dap1 cells harboring the control vector YEplac195 (VEC),
a multicopy expression plasmid encoding HEM1 (pJM63), or a multicopy expression plasmid encoding HEM2
(pJM64) were tested for growth on synthetic dextrose (SD) medium lacking uracil (rows 1– 6) or the same
medium containing 0.015% MMS (rows 7–12) or 10 M itraconazole (rows 13–18). High copy expression of
HEM1 and HEM2 suppressed the susceptibility of dap1 cells to MMS but not itraconazole. B, wild-type (rows
1–3 and 7–9) and dap1 (rows 4 – 6 and 10 –12) cells harboring the control vector YEplac195 or multicopy
plasmids encoding HEM2 (pJM64) or ERG11 (pRH4) were tested for growth on synthetic dextrose medium
lacking uracil (rows 1– 6) or the same medium containing 100 g/ml BPS (rows 7–12). High level Erg11 expres-
sion suppressed loss of Dap1, whereas Hem2 did not. C, an azole Erg11 inhibitor increases susceptibility to BPS.
Wild-type RCY409-2a were serially diluted and tested for growth on YPD plates containing 2 M itraconazole
(row 2), 100 M BPS (row 3), or the two compounds combined (row 4).
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amutation in ERG25/sterol C-5methyloxidase causes sensitiv-
ity to low iron (43). However, it is unlikely that dap1 cells are
sensitive to low iron solely because of low levels of ergosterol.
Because conditions that have a modest effect on ergosterol lev-
els (i.e. overexpression of ERG11) can suppress low iron sensi-
tivity in dap1 mutants, it is likely that the balance of sterol
intermediates affects iron metabolism rather than ergosterol
levels per se.
Deletion ofDAP1 causes accumulation of the sterol interme-
diates lanosterol (the Erg11 substrate) and episterol (the Erg3
substrate) and of the sterol ergosta-5,7-dienol (4). Lanosterol
accumulation can be suppressed by overexpressing ERG11,
which restores azole resistance to dap1mutants and triggers a
marked accumulation of episterol and ergosta-5,7-dienol (8).
Episterol presumably accumulates becauseDap1 is required for
the activity of Erg3/sterol C-5 desaturase (Fig. 7) (44), which is
a highly conserved protein that is activated by cytochrome b5 (6,
45), with which Dap1 shares structural homology and heme
binding activity. In addition, Erg3 is also proposed to bind to
iron through a series of coordinated histidine residues (43, 46),
FIGURE 4. Dap1 is induced by azole antifungal drugs. A, three HA epitope
tag sequences were integrated at the 3 end of the DAP1 open reading frame.
Dap1 was detected by Western blot in haploid and diploid strains. Lanes 1
contained the untagged haploid strain RCY408-1d, whereas lanes 2 and 3
contained the epitope-tagged strains RCY408-1b and RCY408-5b, respec-
tively. Two untagged strains were mated to yield the strain RCY410 (lane 5),
whereas the epitope-tagged strains in lanes 2 and 3 were mated to yield the
diploid strain RCY411 (lane 4). HA-tagged Dap1 was detected as a 27 kDa
band only in the strains containing the epitope-tagged DAP1 alleles. A parallel
Western blot of the same samples was probed with an antibody to tubulin as
a loading control (bottom). B, Dap1 is induced by itraconazole. No Dap1 was
detected in the untagged strain RCY408-1d (lane 1). The Dap1-HA-expressing
strain RCY408-1b was untreated (untr) (lane 2) or treated with 0.1, 0.5, or 1 M
itraconazole for 90 min, and extracts were analyzed by Western blot for HA
(top) or tubulin (bottom). Dap1 expression increased 14-fold relative to tubu-
lin following itraconazole treatment. C–F, Dap1 localizes to punctate sites in
the cytoplasm. Diploid cells expressing Dap1-HA (C and D) or untagged Dap1
(E and F) were stained with an anti-HA antibody and detected with a fluores-
cein isothiocyanate-labeled secondary antibody. Cells were visualized by flu-
orescence (C and E) or bright field microscopy (D and F). C, Dap1 localized to
bright cytoplasmic spots. E, in the RCY410 strain, containing the native,
untagged DAP1 gene, punctate cytoplasmic staining was not detected. The
strains RCY410 and RCY411 differed only by the HA epitope tag cassette adja-
cent to DAP1 and were stained at the same time using the same conditions.
The punctate staining pattern observed for RCY411 was detected in at least
five separate experiments.
FIGURE 5. Dap1 does not co-fractionate with mitochondrial or lipid par-
ticle markers. RCY411 cells were lysed and separated on a 0 – 60% discontin-
uous sucrose gradient, and fractions from the gradient were collected and
analyzed by Western blot. A, HA-tagged Dap1 was detected in fraction 2,
which overlapped with the late endosomal marker Ypt7 (B) and partially over-
lapped with the late endosomal marker Pep12 (C). The lipid particle protein
Erg6 was detected in fractions 7–9 (D), whereas the mitochondrial marker
Por1 (E) was detected in fractions 7 and 8. F, the putative Dap1-interacting
protein Pma1 localized to fraction 6. G, the Erg11 protein, a target of Dap1,
localized in multiple subcellular fractions and overlapped partially with Dap1.
H, in immunofluorescence studies, Erg11 was fused to a single Myc epitope
tag sequence and expressed from the plasmid pRH7 in the diploid strain
RCY411 and showed a granular staining pattern.
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and its substrate accumulates slightly under conditions of low
iron (Fig. 2). It is intriguing to speculate that altered ironmetab-
olism in dap1 cells may inhibit Erg3. One potential clue to the
activation of Erg3 by Dap1 is that treatment of dap1 cells with
heme suppresses lanosterol accumulation (i.e. activates Erg11)
but has little effect on episterol accumulation (8), suggesting a
nonheme role for activating Erg3.
Under low iron conditions, dap1 cells accumulate squa-
lene, suggesting a defect in Erg1/squalene epoxidase. Erg1 is an
oxygen-requiring enzyme that is inhibited by the allylamine
class of antifungal drugs (1). Although squalene was one of the
primary sterols to accumulate in iron-deprived dap1 cells,
overexpression of ERG1 did not restore viability to dap1 cells
under low iron conditions, suggesting that defective Erg1 activ-
ity is not solely responsible for their defective growth.
The common target of Dap1 and its homologues is P450
protein activation, and this activity is shared among the S. cer-
evisiae, S. pombe (9), and rodent (12) Dap1 homologues. Mam-
malian Dap1 homologues are highly expressed in the liver, kid-
ney, and adrenal, which are sites of P450 activity (10, 47, 48),
andmammalianDap1 homologues localize tomicrosomal frac-
tions, including the endoplasmic reticulum (49, 50), which are
also common sites for P450 proteins. The exception to this rule
is in neuronal cells, where somemammalian Dap1 homologues
also localize to the cell membrane (51, 52). Both the S. pombe
Dap1 and human PGRMC1 bind directly to Cyp51 and other
P450 proteins (9). In contrast, we have not detected a stable
interaction between Dap1 and Erg11 in S. cerevisiae, and our
analysis suggests only a partial overlap in their localization. Fur-
thermore, Dap1-Erg11 complexes have not been detected using
genome-wide proteomic screens or two-hybrid analyses. S. cer-
evisiae Dap1 differs from its mammalian and S. pombe homo-
logues in that it lacks a membrane-spanning sequence, and it is
possible that this sequence is required for a stable interaction
with Erg11.
Based on the model proposed above, Dap1 probably regu-
lates vacuolar structure via sterol synthesis. Ergosterol is nec-
FIGURE 6. Cells lacking Dap1 have vacuolar phenotypes. Wild-type
RCY409-2a cells (A and C) and dap1 RCY409-4b cells (B and D) were incu-
bated with the fluorescent dye FM4-64, which stains the vacuolar membrane,
and analyzed by bright field microscopy (A and B) or fluorescent microscopy
(C and D). The inverted images of C and D are shown for improved contrast. In
wild-type cells, vacuoles stained as round shapes, whereas a significant num-
ber of dap1 cells exhibited irregular vacuoles, including multiple smaller
vacuoles. E, wild-type (wt) (RCY409-2a) or dap1 (RCY456) cells harboring a
control plasmid, YEplac181 (VEC.), or the CCC1 high copy plasmid pSCCC1
(CCC1) and a FET3-lacZ reporter construct were tested for -galactosidase
activity. High copy CCC1 expression increased -galactosidase activity in
wild-type cells, with a 40% decrease in CCC1-directed activity in dap1 cells.
Error bars, S.D. between individual measurements. F, FET3 transcription was
assayed by reverse transcription-PCR in wild-type (RCY409-2a) or dap1
(RCY456) cells harboring a control plasmid, YEplac181, or the CCC1 high copy
plasmid pSCCC1. Primers for the SCS2 transcript were included in the same
reaction (the product is the lower band) and served as a loading control
(marked CON). The changes in the FET3/CON ratio relative to lane 2 are shown
below the gel. Lane 1, a control for lane 3, in which reverse transcriptase was
omitted from the cDNA synthesis reaction. All of the assays were performed
at least in triplicate.
FIGURE 7. A model in which Dap1 regulates heme and ergosterol synthe-
sis and iron metabolism. Iron is imported into the cell and is incorporated
into heme, among other molecules. Dap1 binds to heme from its endosomal
locale and activates Erg11 and Erg3, promoting sterol synthesis. Erg11 cata-
lyzes the demethylation of lanosterol, an essential step in ergosterol synthe-
sis, and some of the downstream metabolites of Erg11 are also detected in
endosomes. Erg1 is also activated by Dap1 under low iron conditions. Our
results do not exclude the possibility that iron plays a role in detoxifying sterol
intermediates that accumulate in cells lacking wild-type Erg11 function
(dashed line, left). There are a number of regulatory interactions between
heme, the sterol pathway, and the uptake of iron, and these are not indicated.
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essary for vacuole formation (53–56), and yeast microsomes
contain a significant fraction of the sterols fecosterol, episterol,
and ergosta-5,7,9(11),22-tetraenol (57–59). Our results suggest
a model in which the apparent vacuolar defects in dap1 cells
limit the extent to which CCC1 sequesters iron in the vacuole.
CCC1 is postulated to act as an ion transporter, andCCC1 over-
expression triggers increased cellular iron uptake (24) and vac-
uolar iron storage (60). These functions are partially dependent
on Dap1, although the mechanism linking these proteins is
unknown.
The localization of Dap1 to intracellular vesicles and the
broad distribution of Erg11 suggest that some steps in P450
activation and sterol synthesis are distributed throughout the
cell. Indeed, green fluorescent protein-tagged forms of Erg2,
Erg3, and Erg25 all localize to a vesicle fraction (35). Further-
more, Dap1 has been previously implicated in endocytosis (4),
and the localization of Dap1 to an endosomal fraction suggests
a role in intracellular transport. Althoughmost sterol-defective
mutants are hyperpermeable to dyes (61), dap1 mutants have
defective dye uptake, particularly at low temperatures (4), sug-
gesting that Dap1 is required for the endocytosis of some com-
pounds (4). In addition, dap1 cells do not display abnormali-
ties in membrane integrity (4) that are typical of erg mutants
(61). The model in Fig. 7 is based on the assumption that the
primary role ofDap1 is in sterol synthesis, although it is possible
that Dap1 contributes to endosome function or vacuole struc-
ture through other, uncharacterized mechanisms.
Although heme is required for sterol synthesis, our results
suggest that heme levels are not limiting for azole drug resist-
ance but are limiting forMMS resistance. In contrast, we found
that iron levels are limiting for azole drug resistance. Although
the presumed target for MMS is DNA, Lum et al. (62) previ-
ously identified HEM1 and HEM2 in a screen for MMS targets
using a genome-wide pool of heterozygous deletion strains.
One interpretation of these findings is thatMMS targets Hem1
and/or Hem2 directly. However, MMS sensitivity in HEM1/
hem1 and HEM2/hem2 strains could also arise from dimin-
ished heme levels due to haploinsufficiency of 5-aminolevuli-
nate synthase and -aminolevulinate dehydratase, respectively.
The results are important, becauseMMSclosely resembles che-
motherapeutic drugs that are used clinically, and our results
suggest a role for heme biosynthesis in susceptibility to chemo-
therapeutic drugs. Indeed, the human Dap1 homologue Hpr6/
PGRMC1 is overexpressed in clinical tumors and cancer cell
lines (50), and inhibition of Hpr6/PGRMC1 causes increased
susceptibility to chemotherapeutic drugs (13).
Iron deficiency is the most prevalent nutritional disorder in
the world, affecting almost two billion people (63), and abnor-
mal iron metabolism contributes to a number of diseases,
including Friedrich’s ataxia, hemochromatosis, aging, and
microbial infections (64). Dap1 has homologues in patho-
genic fungi, including Candida species, and our results sug-
gest that Dap1 homologues may have a role in iron metabo-
lism in those organisms. If so, Dap1 homologues may be
useful as targets for therapeutics, particularly in combina-
tion with other antifungal agents or under conditions lead-
ing to deprivation of available iron. There are also Dap1
homologues in higher eukaryotic species, including mam-
mals (10, 47, 65), and the rodent and human Dap1 homo-
logues bind to heme (12). However, the role of these proteins
in iron metabolism has not been examined.
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